

Athalia Rachel Pyzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2636798/publications.pdf>

Version: 2024-02-01

19
papers

301
citations

1478505

6
h-index

1372567

10
g-index

19
all docs

19
docs citations

19
times ranked

703
citing authors

#	ARTICLE	IF	CITATIONS
1	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1791-1801.	1.4	130
2	Myeloid-derived suppressor cells as effectors of immune suppression in cancer. <i>International Journal of Cancer</i> , 2016, 139, 1915-1926.	5.1	80
3	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 126, 354-362.	1.4	31
4	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	1.4	30
5	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3887-3898.	3.6	12
6	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2304-2314.	4.1	10
7	Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression. <i>Blood</i> , 2014, 124, 2072-2072.	1.4	3
8	MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2473-2473.	1.4	2
9	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 387-387.	1.4	2
10	MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. <i>Blood</i> , 2016, 128, 2871-2871.	1.4	1
11	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 808-808.	1.4	0
12	Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 2303-2303.	1.4	0
13	Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression. <i>Blood</i> , 2014, 124, 226-226.	1.4	0
14	Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1. <i>Blood</i> , 2014, 124, 3378-3378.	1.4	0
15	MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2015, 126, 643-643.	1.4	0
16	Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3659-3659.	1.4	0
17	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4175-4175.	1.4	0
18	Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2016, 128, 703-703.	1.4	0

#	ARTICLE	IF	CITATIONS
19	A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma. <i>Blood</i> , 2016, 128, 4484-4484.	1.4	0